When was OptiNose founded?

OptiNose was founded in 2000 and raised its 1st funding round 10 years after it was founded.

Where is OptiNose located?

OptiNose is headquartered in Morrisville, United States. It is registered at Yardley, Pennsylvania.

How many employees does OptiNose have?

As of Jun 30, 2026, the latest employee count at OptiNose is 50.

Is OptiNose a funded company?

OptiNose is a funded company, having raised a total of $120M across 10 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jun 07, 2010.

How much is OptiNose worth?

The last known valuation of OptiNose was $***** as of Mar 19, 2025.

When was the latest funding round of OptiNose?

OptiNose's latest funding was a $***** Post IPO round on May 10, 2024, with participation from 0 investor.

What is the annual revenue of OptiNose?

Annual revenue of OptiNose is between $50M and $100M as on Dec 31, 2024

Where does OptiNose rank among its competitors?

OptiNose ranks 7th amongst 74 active competitors, of which 20 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Nebu~Flow, which secured $2.69M in Jun, 2026.

Who are the top competitors of OptiNose?

OptiNose's top competitors include MannKind Corp, Impel NeuroPharma and Beyond Air. Among them, Nebu~Flow secured the most recent funding round in June, 2026.

OptiNose - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is OptiNose an acquired company?

OptiNose got acquired by Paratek Pharma on Mar 19, 2025.

Company Details

OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.

Website: optinose.com
Registered Address: Yardley, Pennsylvania

Key Metrics

Founded Year

2000

Location

Morrisville, United States

Stage

Acquired

Total Funding

$120M in 10 rounds

Latest Funding Round

Post IPO, May 10, 2024, $*****

Last Known Valuation

$***** as on Mar 19, 2025

Investors

Fidelity Investments & 7 more

Ranked

7^th among 74 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2024

Employee Count

50 as on Jun 30, 2026

Similar Companies

MannKind Corp & 84 more

Exit Details

Acquired by Paratek Pharma (Mar 19, 2025)

View OptiNose's full profile

OptiNose is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Optinose, Inc. CIN: 27-2905255 , United States, Active	May 25, 2010	$50M - $100M (As on Dec 31, 2024)	132 (As on Dec 31, 2023)	-
OPTINOSE US, INC. CIN: 272905255 , United States, Active	Dec 26, 999	-	130 (As on Dec 31, 2024)	-

OptiNose got acquired by Paratek Pharma on Mar 19, 2025 at an acquisition amount of $*****.

Click here to take a look at OptiNose's acquisition in detail

OptiNose has raised a total funding of $120M over 10 rounds. Its first funding round was on Jun 07, 2010. OptiNose has 8 institutional investors.

Here is the list of recent funding rounds of OptiNose:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 10, 2024	5452146	Post IPO	3792559	2213344	7016004	2183825
Nov 28, 2021	4405405	Post IPO	5963357	6345349	5879175	8342155
Aug 19, 2020	3382068	Post IPO	5303175	4167260	4457648	9747252

Access funding benchmarks and valuations. Sign up today!

View details of OptiNose's funding rounds and investors

OptiNose's employee count trend

OptiNose has 50 employees as of Jun 26. Here is OptiNose's employee count trend over the years:

Uncover OptiNose's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OptiNose include MannKind Corp, Impel NeuroPharma and Beyond Air. Here is the list of Top 10 competitors of OptiNose, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
2nd	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Norwest & 7 others	63/100
3rd	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	57/100
4th	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Frazier Healthcare Partners ... & 16 others	57/100
5th	Qnovia 2018, Richmond (United States), Series B	Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals	$50M	Blue Ledge Capital, Evolution VC Partners ... & 4 others	55/100
6th	Iconovo 2013, Lund (Sweden), Public	Develops inhalation devices	$3.56M	Smile Incubator, Eiffel Investment Group & 2 others	55/100
7th	OptiNose 2000, Morrisville (United States), Acquired	Developer of smart devices for nasal drug delivery	$120M	Foresite Capital, Fidelity Investments & 6 others	53/100
8th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	52/100
9th	Nebu~Flow 2019, Glasgow (United Kingdom), Series A	Developer of aerosol delivery platform technology	$7.97M	Foresight Group, SCVC & 8 others	51/100
10th	Neurelis 2007, Encinitas (United States), Series D	Therapeutics for CNS disorders	$221M	HBM Healthcare Investments, LYZZ Capital & 4 others	51/100